Evercore ISI Group maintains Regeneron Pharmaceuticals at Outperform, raises price target to $1075 from $900

What happened

Evercore ISI Group kept its Outperform rating on Regeneron Pharmaceuticals and raised its price target to $1075 from $900. The new target was described as 19.4% higher and implied 15.9% upside from the October 30 closing price of $927.89.

Confirmed

Global impact / market context

A higher analyst target can influence investor expectations, but it is not a company forecast or a guaranteed return. If investors act on the more optimistic view, demand for Regeneron shares could rise; the article gives no evidence of an actual market response.

Analyst inference

The article lists five recent analyst targets, ranging from $875 to $1175, showing differing views on Regeneron’s value. The raised Evercore target is one estimate among several, and the article reports no changes to the company’s operations or financial outlook.

Confirmed

What to watch

1. Compare future analyst targets and ratings with this $1075 target; continued upward revisions could reinforce optimism, while lower targets would show that views remain divided. Analyst inference
2. Track whether later analyst notes change their ratings or price targets for Regeneron; the article lists five recent targets ranging from $875 to $1175, showing differing views. Analyst inference
3. The article reports that the $1075 target implies 15.9% upside from the October 30 close of $927.89; this is an estimate, not a promised return. Confirmed

Evidence

• Original source link unavailable